IBDEI0G7 ; ; 12-MAY-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 12, 2016
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16233,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16233,1,3,0)
 ;;=3^Hodgkin Lymphoma,Nodular Lymphocyte,Extrnod & Solid Org Site
 ;;^UTILITY(U,$J,358.3,16233,1,4,0)
 ;;=4^C81.09
 ;;^UTILITY(U,$J,358.3,16233,2)
 ;;=^5001400
 ;;^UTILITY(U,$J,358.3,16234,0)
 ;;=C81.40^^64^782^12
 ;;^UTILITY(U,$J,358.3,16234,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16234,1,3,0)
 ;;=3^Hodgkin Lymphoma,Lymphocyte-Rich,Unspec Site
 ;;^UTILITY(U,$J,358.3,16234,1,4,0)
 ;;=4^C81.40
 ;;^UTILITY(U,$J,358.3,16234,2)
 ;;=^5001431
 ;;^UTILITY(U,$J,358.3,16235,0)
 ;;=C81.49^^64^782^11
 ;;^UTILITY(U,$J,358.3,16235,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16235,1,3,0)
 ;;=3^Hodgkin Lymphoma,Lymphocyte-Rich,Extrnod & Solid Org Sites
 ;;^UTILITY(U,$J,358.3,16235,1,4,0)
 ;;=4^C81.49
 ;;^UTILITY(U,$J,358.3,16235,2)
 ;;=^5001440
 ;;^UTILITY(U,$J,358.3,16236,0)
 ;;=C81.30^^64^782^10
 ;;^UTILITY(U,$J,358.3,16236,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16236,1,3,0)
 ;;=3^Hodgkin Lymphoma,Lymphocyte Depleted,Unspec Site
 ;;^UTILITY(U,$J,358.3,16236,1,4,0)
 ;;=4^C81.30
 ;;^UTILITY(U,$J,358.3,16236,2)
 ;;=^5001421
 ;;^UTILITY(U,$J,358.3,16237,0)
 ;;=C81.39^^64^782^9
 ;;^UTILITY(U,$J,358.3,16237,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16237,1,3,0)
 ;;=3^Hodgkin Lymphoma,Lymphocyte Depleted,Extrnod & Solid Org Site
 ;;^UTILITY(U,$J,358.3,16237,1,4,0)
 ;;=4^C81.39
 ;;^UTILITY(U,$J,358.3,16237,2)
 ;;=^5001430
 ;;^UTILITY(U,$J,358.3,16238,0)
 ;;=C81.20^^64^782^14
 ;;^UTILITY(U,$J,358.3,16238,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16238,1,3,0)
 ;;=3^Hodgkin Lymphoma,Mixed Cellularity,Unspec Site
 ;;^UTILITY(U,$J,358.3,16238,1,4,0)
 ;;=4^C81.20
 ;;^UTILITY(U,$J,358.3,16238,2)
 ;;=^5001411
 ;;^UTILITY(U,$J,358.3,16239,0)
 ;;=C81.29^^64^782^13
 ;;^UTILITY(U,$J,358.3,16239,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16239,1,3,0)
 ;;=3^Hodgkin Lymphoma,Mixed Cellularity,Extrnod & Solid Org Sites
 ;;^UTILITY(U,$J,358.3,16239,1,4,0)
 ;;=4^C81.29
 ;;^UTILITY(U,$J,358.3,16239,2)
 ;;=^5001420
 ;;^UTILITY(U,$J,358.3,16240,0)
 ;;=C81.10^^64^782^18
 ;;^UTILITY(U,$J,358.3,16240,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16240,1,3,0)
 ;;=3^Hodgkin Lymphoma,Nodular Sclerosis,Unspec Site
 ;;^UTILITY(U,$J,358.3,16240,1,4,0)
 ;;=4^C81.10
 ;;^UTILITY(U,$J,358.3,16240,2)
 ;;=^5001401
 ;;^UTILITY(U,$J,358.3,16241,0)
 ;;=C81.19^^64^782^17
 ;;^UTILITY(U,$J,358.3,16241,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16241,1,3,0)
 ;;=3^Hodgkin Lymphoma,Nodular Sclerosis,Extrnod & Solid Org Sites
 ;;^UTILITY(U,$J,358.3,16241,1,4,0)
 ;;=4^C81.19
 ;;^UTILITY(U,$J,358.3,16241,2)
 ;;=^5001410
 ;;^UTILITY(U,$J,358.3,16242,0)
 ;;=C81.99^^64^782^8
 ;;^UTILITY(U,$J,358.3,16242,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16242,1,3,0)
 ;;=3^Hodgkin Lymphoma,Extrnod & Solid Org Sites,Unspec
 ;;^UTILITY(U,$J,358.3,16242,1,4,0)
 ;;=4^C81.99
 ;;^UTILITY(U,$J,358.3,16242,2)
 ;;=^5001460
 ;;^UTILITY(U,$J,358.3,16243,0)
 ;;=C82.90^^64^782^6
 ;;^UTILITY(U,$J,358.3,16243,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16243,1,3,0)
 ;;=3^Follicular Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,16243,1,4,0)
 ;;=4^C82.90
 ;;^UTILITY(U,$J,358.3,16243,2)
 ;;=^5001541
 ;;^UTILITY(U,$J,358.3,16244,0)
 ;;=C82.99^^64^782^5
 ;;^UTILITY(U,$J,358.3,16244,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16244,1,3,0)
 ;;=3^Follicular Lymphoma,Extrnod & Solid Org Sites
 ;;^UTILITY(U,$J,358.3,16244,1,4,0)
 ;;=4^C82.99
 ;;^UTILITY(U,$J,358.3,16244,2)
 ;;=^5001550
 ;;^UTILITY(U,$J,358.3,16245,0)
 ;;=C83.70^^64^782^2
 ;;^UTILITY(U,$J,358.3,16245,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16245,1,3,0)
 ;;=3^Burkitt Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,16245,1,4,0)
 ;;=4^C83.70
 ;;^UTILITY(U,$J,358.3,16245,2)
 ;;=^5001591
 ;;^UTILITY(U,$J,358.3,16246,0)
 ;;=C83.79^^64^782^1
 ;;^UTILITY(U,$J,358.3,16246,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16246,1,3,0)
 ;;=3^Burkitt Lymphoma,Extrnod & Solid Org Sites
 ;;^UTILITY(U,$J,358.3,16246,1,4,0)
 ;;=4^C83.79
 ;;^UTILITY(U,$J,358.3,16246,2)
 ;;=^5001600
 ;;^UTILITY(U,$J,358.3,16247,0)
 ;;=C96.9^^64^782^27
 ;;^UTILITY(U,$J,358.3,16247,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16247,1,3,0)
 ;;=3^Malig Neop Lymphoid/Hematopoietic/Related Tissue,Unspec
 ;;^UTILITY(U,$J,358.3,16247,1,4,0)
 ;;=4^C96.9
 ;;^UTILITY(U,$J,358.3,16247,2)
 ;;=^5001864
 ;;^UTILITY(U,$J,358.3,16248,0)
 ;;=C96.4^^64^782^3
 ;;^UTILITY(U,$J,358.3,16248,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16248,1,3,0)
 ;;=3^Dendritic Cells Sarcoma
 ;;^UTILITY(U,$J,358.3,16248,1,4,0)
 ;;=4^C96.4
 ;;^UTILITY(U,$J,358.3,16248,2)
 ;;=^5001861
 ;;^UTILITY(U,$J,358.3,16249,0)
 ;;=C83.50^^64^782^23
 ;;^UTILITY(U,$J,358.3,16249,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16249,1,3,0)
 ;;=3^Lymphoblastic Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,16249,1,4,0)
 ;;=4^C83.50
 ;;^UTILITY(U,$J,358.3,16249,2)
 ;;=^5001581
 ;;^UTILITY(U,$J,358.3,16250,0)
 ;;=C83.59^^64^782^22
 ;;^UTILITY(U,$J,358.3,16250,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16250,1,3,0)
 ;;=3^Lymphoblastic Lymphoma,Extrnod & Solid Org Sites
 ;;^UTILITY(U,$J,358.3,16250,1,4,0)
 ;;=4^C83.59
 ;;^UTILITY(U,$J,358.3,16250,2)
 ;;=^5001590
 ;;^UTILITY(U,$J,358.3,16251,0)
 ;;=C94.40^^64^782^40
 ;;^UTILITY(U,$J,358.3,16251,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16251,1,3,0)
 ;;=3^Panmyelosis w/ Myelofibrosis,Acute,Not in Remission
 ;;^UTILITY(U,$J,358.3,16251,1,4,0)
 ;;=4^C94.40
 ;;^UTILITY(U,$J,358.3,16251,2)
 ;;=^5001843
 ;;^UTILITY(U,$J,358.3,16252,0)
 ;;=C94.41^^64^782^38
 ;;^UTILITY(U,$J,358.3,16252,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16252,1,3,0)
 ;;=3^Panmyelosis w/ Myelofibrosis,Acute,In Remission
 ;;^UTILITY(U,$J,358.3,16252,1,4,0)
 ;;=4^C94.41
 ;;^UTILITY(U,$J,358.3,16252,2)
 ;;=^5001844
 ;;^UTILITY(U,$J,358.3,16253,0)
 ;;=C94.42^^64^782^39
 ;;^UTILITY(U,$J,358.3,16253,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16253,1,3,0)
 ;;=3^Panmyelosis w/ Myelofibrosis,Acute,In Relapse
 ;;^UTILITY(U,$J,358.3,16253,1,4,0)
 ;;=4^C94.42
 ;;^UTILITY(U,$J,358.3,16253,2)
 ;;=^5001845
 ;;^UTILITY(U,$J,358.3,16254,0)
 ;;=D47.1^^64^782^36
 ;;^UTILITY(U,$J,358.3,16254,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16254,1,3,0)
 ;;=3^Myeloproliferative Disease,Chr
 ;;^UTILITY(U,$J,358.3,16254,1,4,0)
 ;;=4^D47.1
 ;;^UTILITY(U,$J,358.3,16254,2)
 ;;=^5002256
 ;;^UTILITY(U,$J,358.3,16255,0)
 ;;=D47.9^^64^782^37
 ;;^UTILITY(U,$J,358.3,16255,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16255,1,3,0)
 ;;=3^Neop Uncrt Behavior Lymphoid/Hematopoietic/Related Tissue,Unspec
 ;;^UTILITY(U,$J,358.3,16255,1,4,0)
 ;;=4^D47.9
 ;;^UTILITY(U,$J,358.3,16255,2)
 ;;=^5002260
 ;;^UTILITY(U,$J,358.3,16256,0)
 ;;=C80.0^^64^782^4
 ;;^UTILITY(U,$J,358.3,16256,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16256,1,3,0)
 ;;=3^Disseminated Malig Neop,Unspec
 ;;^UTILITY(U,$J,358.3,16256,1,4,0)
 ;;=4^C80.0
 ;;^UTILITY(U,$J,358.3,16256,2)
 ;;=^5001388
 ;;^UTILITY(U,$J,358.3,16257,0)
 ;;=D47.2^^64^782^28
 ;;^UTILITY(U,$J,358.3,16257,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16257,1,3,0)
 ;;=3^Monoclonal Gammopathy
 ;;^UTILITY(U,$J,358.3,16257,1,4,0)
 ;;=4^D47.2
 ;;^UTILITY(U,$J,358.3,16257,2)
 ;;=^5002257
 ;;^UTILITY(U,$J,358.3,16258,0)
 ;;=C90.00^^64^782^29
 ;;^UTILITY(U,$J,358.3,16258,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16258,1,3,0)
 ;;=3^Multiple Myeloma,Not in Remission
 ;;^UTILITY(U,$J,358.3,16258,1,4,0)
 ;;=4^C90.00
 ;;^UTILITY(U,$J,358.3,16258,2)
 ;;=^5001752
 ;;^UTILITY(U,$J,358.3,16259,0)
 ;;=C84.00^^64^782^31
 ;;^UTILITY(U,$J,358.3,16259,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16259,1,3,0)
 ;;=3^Mycosis Fungoides,Unspec Site
 ;;^UTILITY(U,$J,358.3,16259,1,4,0)
 ;;=4^C84.00
 ;;^UTILITY(U,$J,358.3,16259,2)
 ;;=^5001621
 ;;^UTILITY(U,$J,358.3,16260,0)
 ;;=C84.09^^64^782^30
